[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"jc-virus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:jc-virus-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100245918","phase-2-cytotoxic-t-lymphocytes-in-treating-patients-with-malignancies-with-bk-andor-jc-virus-100245918",false,"NCT02479698","Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and\u002For JC Virus","Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by Ex Vivo Expansion in Patients With BK Virus Infection and JC Virus Infection","Inclusion Criteria:\n\n* Patients ≥ 2 years. English and non-English speaking patients are eligible.\n* Immunocompromised patients; and\u002For Non-immunocompromised patients with PML\u002FJC virus Encephalitis; and\u002For patients with any type of malignancies; and\u002For HIV\u002FAIDs; and\u002For history of solid organ transplant; and\u002For Merkel polyoma-virus related Merkel cell tumor(s) with measurable disease on imaging per RECIST criteria.\n* Patients with microscopic hematuria OR biopsy proven BK nephritis and urine or blood PCR positive for BK virus and\u002For JC viral encephalitis and\u002For JC end-organ disease and\u002For polyomavirus.\n* Clinical status at enrollment to allow tapering of steroids to less than 0.5 mg\u002Fkg\u002Fday of prednisone.\n* Patients who are currently receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for CTL infusion.\n* Written informed consent and\u002For signed assent from patient, parent or guardian. Patients with cognitive impairments are eligible.\n* Negative pregnancy test in female patients of childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of child bearing potential must be willing to use an effective contraceptive measure while on study.\n* Patients enrolled on this study may be enrolled on other IND studies at the discretion of the PI.\n* Patients may be re-enrolled in the protocol should the infection re-occur, provided they meet all the other eligibility criteria at the moment of re-enrollment.\n\nExclusion Criteria:\n\n* Patients receiving prednisone \\> 0.5 mg\u002Fkg\u002Fday at time of enrollment, or have received ATG within 14 days or have received donor lymphocyte infusion (DLI) or Campath within 28 days of enrollment.\n* Patients with other uncontrolled infections (except HIV\u002FAIDS). For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection\n* Patients with active acute (GVHD) grades II-IV","ALL",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and\u002For JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and\u002For JC virus.",[25,26,27,28,29,30,31,32],"Acquired Immunodeficiency Syndrome","BK Virus Infection","Human Immunodeficiency Virus","JC Virus Infection","Malignant Neoplasm","Merkel Cell Carcinoma","Merkel Cell Polyomavirus Infection","Viral Encephalitis","RECRUITING","2026-06-10",{"date":36,"type":37},"2026-06-12","ACTUAL",{"date":39,"type":37},"2015-07-23",{"date":41,"type":19},"2027-07-31",{"name":43,"class":44},"M.D. Anderson Cancer Center","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100447036","phase-1-study-assessing-the-feasibility-safety-and-efficacy-of-genetically-engineered-glucocorticoid-receptor-knock-out-virus-specific-ctl-lines-for-viral-infections-in-immunosuppressed-cancer-patients-100447036","NCT05101213","Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients","Inclusion Criteria:\n\n* Patients \\> or = 18 years of age or older.\n* For BKV, ADV or CMV infections: Prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using bone marrow, peripheral blood stem cells or single or double umbilical cord blood. For JC virus and COVID19 infection: no prior hematopoietic stem cell transplantation (HSCT) is required.\n* For BKV infection, patients need to have polymerase chain reaction (PCR) positive for BKV (in peripheral blood or urine) with consistent clinical symptoms.\n* For ADV infection, patients need to have PCR positive for ADV in peripheral blood AND\u002FOR patients need to fit criteria of probable or definitive adenovirus organ disease.\n* For CMV infection, patients need to have PCR positive for CMV in peripheral blood AND\u002FOR patients need to fit criteria of probable or definitive CMV disease.\n* For JCV, patients need to have documented JC viral encephalitis or JC end-organ disease.\n* For COVID-19 infection, patients need to have COVID-19 related pneumonia\u002Facute respiratory distress syndrome (ARDS) to be enrolled, defined as patients with a positive COVID-19 test (bronchoalveolar lavage \\[BAL\\], nasal or pharyngeal) and radiological and clinical signs of pneumonia or ARDS.\n* Written informed consent from patient or designated power of attorney.\n* Subjects are also are required to consent to PA17-0483 for long term follow up per the guidelines set forth by the Food and Drug Administrations' (FDA's) Biologic Response Modifiers Advisory Committee (BRMAC).\n* Negative pregnancy blood test in female patients of childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of child bearing potential must be willing to use at least two forms of birth control during the study and for at least 6 months after stopping treatment. Acceptable forms of birth control include intrauterine device (IUD), hormonal methods (birth control pills, injections, and implants), condoms, diaphragms, tubal ligation, or vasectomy.\n\nExclusion Criteria:\n\n* Patients who have received anti-thymocyte globulin (ATG) within 14 days or have received donor lymphocyte infusion (DLI) or campath within 28 days of enrollment.\n* Patients with other uncontrolled infections (excluding human immunodeficiency virus \\[HIV\\]\u002Facquired immunodeficiency syndrome \\[AIDS\\]). For bacterial infections, patients must be receiving definitive therapy and have signs of improving infection prior to enrollment as determined by the principal investigator (PI). For fungal infections, patients must be receiving definitive systemic anti-fungal therapy and have signs of improving infection prior to enrollment as determined by the PI.\n* Patients with active steroid refractory graft versus host disease (GVHD).\n* Patients on immunosuppressive therapy other than tacrolimus, sirolimus or steroids\n* Active and uncontrolled relapse of malignancy. Patients with controlled malignancy on maintenance therapy would be eligible for the study.","18 Years",{"count":54,"type":19},30,[56],"PHASE1","This phase I trial tests the feasibility and safety of genetically modified cytotoxic T-lymphocytes in controlling infections caused by adenovirus (ADV), BK virus (BKV), cytomegalovirus (CMV), JC virus (JCV), or COVID-19 in immunocompromised patients with cancer. Viral infections are a leading cause of morbidity and mortality after hematopoietic stem cell transplantation, and therapeutic options for these infections are often complicated by associated toxicities. Genetically modified cytotoxic T-lymphocytes (CTLs) are designed to kill a specific virus that can cause infections. Depending on which virus a patient is infected with (ADV, BKV, CMV, JCV, or COVID-19), the CTLs will be designed to specifically attack that virus. Giving genetically modified CTLs may help to control the infection.",[59,26,60,61,28,62,63],"Adenovirus Infection","Cytomegaloviral Infection","Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","Symptomatic COVID-19 Infection Laboratory-Confirmed","2026-04-13",{"date":66,"type":37},"2026-04-16",{"date":68,"type":37},"2023-01-06",{"date":70,"type":19},"2027-01-31",{"name":43,"class":44},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":79,"enrollmentInfo":4,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":91,"locationsCount":4},"100600984","tetravi-expanded-access-program-100600984","NCT07104591","TETRAVI Expanded Access Program","Expanded Access Use of Multivirus-Specific Cytotoxic T-Lymphocytes for Pediatric Patients With EBV, CMV, Adenovirus, or BK Virus Infections Post Allogeneic Stem Cell Transplant","Inclusion Criteria:\n\n* Patients \\\u003C18 years of age.\n* Patients who have undergone myeloablative or non-myeloablative allogeneic HSCT or CAR T therapy in the Sate of Texas (USA).\n* Have persistent, increasing, or recurrent infections with EBV, CMV, adenovirus, or BK virus despite standard treatment.\n* Treating physician must be based in Texas.\n* Must obtain IRB approval and submit a protocol to FDA with Letter of Authorization from Baylor.\n\nExclusion Criteria:\n\n* Patients with active uncontrolled infections unrelated to the viruses mentioned.\n* Use of certain immunosuppressive agents within 28 days.\n* Serious uncontrolled medical conditions or relapse of underlying disease.","17 Years","EXPANDED_ACCESS","This Expanded Access Program (EAP) allows qualified physicians within Texas to obtain access to multivirus-specific cytotoxic T lymphocytes (VSTs) developed under Baylor College of Medicine's TETRAVI program (NCT04013802) for the treatment of persistent or recurrent infections with EBV, CMV, adenovirus, or BK virus in pediatric patients being treated in Texas who have received allogeneic stem cell transplants and have no other suitable therapeutic options.",[83,84,59,26,28,85,86],"Epstein-Barr Virus Infection","Cytomegalovirus Infections","Viral Infections Post-Transplant","Post-Allogeneic Stem Cell Transplant Complications","AVAILABLE","2025-07-29",{"date":90,"type":37},"2025-08-05",{"name":92,"class":44},"Baylor College of Medicine"]